Amarin Corp Plc (AMRN)

[Birdbrain Ideas]

I agree that the WSJ article wasn't terrible. Anything that promotes the main ingredient of Vascepa as a really good thing helps to refute any criticism of Reduce It and its results. And it helps to put Vascepa on the map for the vast majority of doctors who don't know about it or understand its benefits. But the research highlighted in this article is in its infancy and is probably a decade away from mass production if great results are produced in trials on humans.